Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation

ADA reports lecture fees from Amgen, Bianex, Eli-Lilly, Er-Kim, Galenica, ITF, Uni-pharma and UCB; PM reports fees for lectures/advisory boards and research grants from Amgen and fees for lectures/advisory boards from UCB, Elpen and Galenica; SAP has nothing to disclose; AK and BK are ANSH laboratories personnel; CSM reports grants through his institution from Merck, Esperion, Abbott, Massachusetts Life Sciences Center and Boehringer Ingellheim; has received personal consulting fees and support with research reagents from Ansh Inc.; collaborative research support from LabCorp Inc.; reports personal consulting fees from Olympus, Genfit, Lumos, Novo Nordisk, Amgen, Corcept, Intercept, 89 Bio, Madrigal, Aligos, Esperion and Regeneron; reports educational activity meals through his institution or national conferences from Esperion, Merck and Boehringer Ingelheim; and travel support and fees from UptoDate, TMIOA, Elsevier and the Cardio Metabolic Health Conference. None is related to this paper. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.16208. Data will be available upon reasonable request.